



ACN 007 988 767  
Phone: +61 8 8234 2660  
Fax: +61 8 8234 6268  
Address: 38 Winwood Street  
Thebarton South Australia 5031  
[www.bresagen.com](http://www.bresagen.com)

## FACSIMILE TRANSMISSION

TO: The Office of International Corporate Finance  
COMPANY: SEC  
FAX NUMBER: 0011 1 202 942 9624  
FROM: Trudy Fenton  
DATE: Monday, 29 April 2002  
SUBJECT: ASX Announcement  
PAGES (Inc. cover) 3



02028728

02 APR 29 AM 11:01

In accordance with our obligation as a 12g3-2(b) filer, number 82-5135, to file home country announcements, please find the following Media Release which was released through the Australian Stock Exchange today –

### ***BresaGen shares in \$US3.5m award from USA Government***

Yours sincerely

A handwritten signature in cursive script, appearing to read 'Trudy Fenton'.

Trudy Fenton  
Corporate Administrator  
[tfenton@bresagen.com.au](mailto:tfenton@bresagen.com.au)

PROCESSED

MAY 14 2002

p  
THOMSON  
FINANCIAL

SUPPL

Handwritten initials 'dlw' followed by the date '4/30'.

If there are any problems with this transmission, call 08 8234 2660

This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution this information or any information this facsimile may contain by anyone other than the addressee, is prohibited. If you have received this document in error, please advise BresaGen by telephone and then return it by mail to the address above. We shall refund in full your costs in doing so.

Monday, 29 April 2002



## **BresaGen shares in \$US3.5m award from USA Government**

The Board of BresaGen announced today that its US affiliate Cellsaurus Inc had become one of the first recipients of the USA Federal Government's funding of human embryonic stem cell research. The funding has come from the National Institutes of Health (NIH) grant of a resource infrastructure enhancement award for human embryonic stem cell (hESC) research. The award to be shared with three other non-listed organisations provides approximately \$US3.5 million over two years.

"This award to Cellsaurus represents one of the first major expenditures by the NIH for supporting human embryonic stem cell research," said Ruth Kirschstein, M.D., Acting NIH Director. "By providing these funds, the NIH is hoping to get these cells into the hands of basic scientists as quickly as possible."

This award will stimulate the use of hESC in basic research by providing funds for expansion, testing, quality assurance, and distribution of existing cell lines that meet the President's criteria for federal funding of research on hESC.

Along with Cellsaurus, three other entities will receive an infrastructure enhancement award: ES Cell International Pty Ltd, of Melbourne, Victoria, Australia; the University of California, San Francisco (UCSF); and the Wisconsin Alumni Research Foundation of Madison, Wisconsin. The four awardees are listed on the NIH Human Embryonic Stem Cell Registry, <http://escr.nih.gov>, and have a combined total of 17 stem cell lines that will be available to scientists for basic research.

"We welcome this practical assistance from the US Federal Government, through the NIH, to enable research in this critical area," said Dr John Smeaton, CEO & President of BresaGen Limited. "This research award complements the product development activities of the Company, supported by the Australian Federal Government via an AusIndustry Start Grant. The recognition of our work by both the American and Australian Federal Governments is gratifying as it acknowledges the importance of the stem cell area."

"I am sure this support will be welcomed by various patient groups who will ultimately benefit from developments in this area," Dr Smeaton commented.

### **For further information contact:**

Dr Chris Juttner  
Vice President, Clinical Development  
BresaGen Limited  
Phone: 08 8234 2660  
Mob: 0408 185 100

Anna Candler,  
The Six Hats Pty Ltd-Investor Relations  
Phone: 02 9252 4489  
Mobile: 0412 995 586

Dr Meera Verma  
Vice President and Chief Operating Officer  
BresaGen Limited  
Phone: 08 8234 2660

**About BresaGen Limited**

BresaGen is a biotechnology company committed to the discovery and commercial development of innovative bio-therapies. Drawing on two decades of experience, the company has earned a reputation for excellence in the fields of reproductive and developmental biology and in the manufacture of recombinant protein pharmaceuticals. The Company has offices and laboratories in Adelaide, Australia and Athens, Georgia USA and is represented by three divisions, Protein Pharmaceuticals, Cell Therapy and Reproductive Biotechnology.

The Cell Therapy division represents a research and development program that takes the company's proprietary position in embryonic stem cell differentiation and primarily applies it to the treatment of neurodegenerative disease. The division also has an extensive program developing catheter and imaging technology for neurosurgical cell delivery.

The Protein Pharmaceuticals division operates a GMP facility with experience in the manufacture of recombinant proteins. The division has a pipeline of human therapeutic candidates in development that include potential treatments for myeloid leukemia, rheumatoid arthritis, and growth hormone deficiency.

The Reproductive Biotechnology division represents a research program developing improved cloning technologies in the pig for accelerated genetic improvement and xenotransplant applications.

**About National Institutes of Health (NIH)**

The NIH is a component of the US Department of Health and Human Services, and the premier US federal agency for biomedical research. See website: <http://www.nih.gov/news/>

*This press release contains forward-looking statements which reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategy, the applicability of the discoveries made therein, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.*